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Abstract:Myasthenia gravis is occasionally associated with thymoma
that needs surgical resection and may progress to severe respiratory
failure. We experienced a rare case of myasthenia crisis during antiviral
therapy for chronic hepatitis C, in whom mediastinal thymoma was
discovered and successfully managed with surgical thymectomy and
meticulous medical care.
A 47-year-old-male patient complained of sudden diplopia 1 week
after stopping 11-week administration of pegylated-interferon and
ribavirin for chronic hepatitis C. Ophthalmologic examinations revealed
ptosis on the right eyelid and restricted right eye movement. Myasthenia
gravis was confirmed by positive repetitive nerve stimulation test and
positive serum antiacetylcholine receptor antibody test, and mediastinal
thymoma was found on chest CT scan. The ocular myasthenia gravis
progressed to respiratory failure even after discontinuing antiviral
treatment but eventually recovered with thymectomy, anticholinesterase
administration, steroid pulse therapy, and prolonged ventilator care. We
describe the clinical features of this life-threatening complication of
interferon treatment along with previous myasthenia crisis cases by
interferon for chronic hepatitis C.
In patients with chronic hepatitis C who is going to receive inter-
feron-based antiviral treatment, physicians need to keep in mind the
potential life-threatening manifestations of myasthenia gravis before
and during antiviral treatment especially when patients complain of
muscular weakness and easy fatigability.
(Medicine 95(21):e3782)
Abbreviations: anti-AChR antibody = anti-acetylcholine receptor
antibody, CHC = chronic hepatitis C, CHC = chronic hepatitis C,
DAA = direct acting antiviral agents, HCV = hepatitis C virus,Rhie, PhD
INTRODUCTION
S tandard care for chronic hepatitis C (CHC) has been acombination of pegylated interferon-alpha (Peg-INFa)
and ribavirin, although this treatment has suboptimal antiviral
efficacy and significant adverse events.1 Even in the latest
treatment recommendation using novel direct acting antiviral
agents, interferon (IFN)-based treatments are still optional.2
The main drawbacks of interferon-based treatment are unsa-
tisfactory response rate and various adverse effects, which often
lead to premature termination of treatment followed by treat-
ment failure. Myasthenia Gravis (MG) is an autoimmune
neuromuscular junction disorder characterized by muscular
weakness and fatigability.3 MG is occasionally associated with
invasive thymoma that needs surgical resection and may pro-
gress to severe respiratory failure.4 Development of MG in
patients with CHC has been rarely reported before or during
antiviral treatment with interferon.5–18 A total of 12 cases of
MG7–18 were reported in association with interferon treatment
for CHC and 6 of them went through myasthenia crisis that
require respiratory support.8,9,11,13,16,18 We experienced a rare
case of myasthenia crisis during antiviral therapy for CHC, in
whom mediastinal thymoma was discovered and successfully
managed with surgical thymectomy and meticulous medical
care. We reviewed the clinical course of this life-threatening
complication of IFN treatment along with the already reported
myasthenia crisis cases in CHC patients.
CASE PRESENTATION
A 47-year-old male patient presented with a complaining of
sudden diplopia that developed one week after 11-week of
antiviral combination treatment for chronic hepatitis C
(Figure 1A). Ophthalmologic examinations revealed ptosis and
restricted eye movement on the right eyelid. He had been on
antiviral combination treatment with Peg-IFN-a2a (180mg/wk)
(Pegasys1; Roche,Basel, Switzerland) and ribavirin (1000mg/d)
(LGRibavirin; LG Life Sciences, Seoul, Korea) for the genotype
1b hepatitis C virus (HCV) infection. The pretreatment serum
HCV RNA level was 2.32 107 IU/mL and AST/ALT levels
were 255/323U/L. At 6-week of treatment, WBC count
decreased to 2500/mm3 and absolute neutrophil count was
725/mm3. The dosage of Peg-IFN-a2a was reduced to 90mg/
wk, but WBC count continued decreasing to 2000/mm3. Five
weeks later, the absolute neutrophil count was 500/mm3 and the
serumHCVRNA levelwas below the limit of detection (<15 IU/
mL). Consequently, the antiviral treatment was promptly dis-
continued and the neutropenia improved on serial blood tests.
One week after discontinuation of antiviral treatment, the patientiplopia and right eye ptosiswas observed.
ye ptosis and upper extremities weakness
. He was immediately hospitalized and
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Baik et al Medicine  Volume 95, Number 21, May 2016initial physical examination was normal except facial palsy with
the right ptosis, mild dyspnea, and upper extremities weakness.
Upon admission, he denied any other oralmedications and had no
history of vascular or thyroid diseases.
On further evaluation, the low rate repetitive nerve stimu-
lation test (Jolly test) andNeostigmine test were positive findings
for myasthenia gravis (Table 1) and serum antiacetylcholine
receptor (anti-AChR) antibody level of 14.95 nmol/L (normal
range: below 0.2 nmol/L). Initial symptoms of ocular MG
progressed to difficulties in chewing and swallowing, followed
by respiratory failure in 3 days. Administration of pyridostigmine
(Mestinon1) 180mg/day was started and chest CT scan was
performed which revealed anterior mediastinal mass measuring
7 cm in its greatest dimension, whereas brain imaging study was
normal (Figure 2). The patient received a surgical thymectomy
and a high-grade thymoma invading pericardium and pleura
(Figure 3) was observed on the pathological examination
of the surgical specimen, which confirmed invasive thymoma
(Type B3, WHO classification). The patient’s respiratory failure
aggravated after surgery, leading to an increased ventilator
dependency. In response to the worsening respiratory condition,
pyridostigmine dose was increased up to 600mg/d and intrave-
nous immunoglobulin and high-dose steroid pulse therapy were
started. Timeline for hospital course and treatment was presented
(Figure 4). After 40 days of intensive care, the patient has his
ocular symptoms back to normal (Figure 1B) and was success-
fullyweaned from themechanical ventilator. Hewas able towalk
FIGURE 1. Ophthalmologic examination. Limited movement of rig
(A). Ptosis and restricted movement on the right upper lid was imon discharge with maintenance medications of steroid and pyr-
idostigmine. However, his serum HCV RNA became detectable
again.DISCUSSION
Treatment for CHC with combination of peg-INF and
ribavirin eradicates HCV RNA in 40% to 50% of treatment-
TABLE 1. Results of Low Rate Repetitive Nerve Stimulation Test
RNST Decrement Amplitude Abductor Digiti quinti Muscle N
2Hz 4.5%
3Hz 6.0%
5Hz 6.7%
Stigmine Test Before Injection
Phonation 6 s
Upward gaze 33 s
Neck flexion 10 s
Arm extension 20 s
Leg elevation 15 s
2 | www.md-journal.comnaive patients infected with HCV genotype 1.2 In early clinical
trials,10% to 14% of treated patients discontinue combination
treatment prematurely due to various adverse events and IFN
was the major concern in most of them.19 Unsatisfactory
response rate and high rate of unbearable side effects have
been the major issues of conventional combination therapy.20
Recently, direct acting antiviral agents (DAA) against
HCV were developed and showed markedly improved clinical
efficacy than the conventional combination treatment in terms
of both potency and safety aspects.2 New standards of treat-
ments using direct acting antivirals are being established and
rapidly replacing the conventional combination therapy. How-
ever, the conventional combination treatment is still widely
prescribed for CHC and IFN is not completely excluded from
some of the DAA-based new regimens yet. Therefore, for the
treatment of CHC it is still major concern of clinicians to cope
with the various side effects of IFN.
MG in patients with CHCwere mostly associated with IFN
treatment, but it may develop without IFN administration. Two
case reports 5,6 described development of MG in CHC patients
who did not receive antiviral treatment. A 35-year-old male
patients with established CHC for several years without any
treatment developed MG5 and a 59-year-old male with liver
cirrhosis as a result of long-standing HCV infection developed
typical MG symptoms and died due to myasthenia crisis.6 The
authors suggested the cross-reactivity between HCV epitopes
and the acetylcholine receptor as the underlying mechanism.
The etiologic roles of various viral infections including HCV
were suggested for the development of MG, but the exact
significance of HCV infection per se is not clear.21
Though MG was not reported in large-scale analyses of
CHC patients who received IFN treatment,22 literatures
eye and eyelid. There was limitation at upper gaze in the right eye
ved after treatment (B).suggesting the association between MG and IFN administration
have been published in the form of case reports.7–18 There were
12 cases of MG by IFN for CHC including 6 myasthenia crisis
(RNST) and Stigmine Test
asalis Muscle Orbicularis Oculi Muscle Trapezius Muscle
50.0% 18.5% 51.8%
41.7% 18.8% 48.1%
42.6% 16.2% 50.7%
20min 40min 60min
9 s 13 s 14 s
38 s 30 s 32 s
15 s 18 s 18 s
50 s 130 s 110 s
19 s 26 s 27 s
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Medicine  Volume 95, Number 21, May 2016 Myasthenia Crisis by Peg-INF in Hepatitis Ccases (Table 2). In case reports of myasthenia crisis that
developed during IFN-based antiviral treatment for CHC, male
patients>44 were most commonly affected and the mean age of
patients was 57 years and mean interval between starting IFN
administration and diagnosis of MG was 4.57 months (6 weeks
to 15 months). The mean duration of IFN treatment was 4.96
months (6 weeks to 15 months). The mean level of anti-AchR
antibody was high as 16.3 nmol/L. The ocular symptom was
the most common presenting symptom. In most patients, respir-
atory distress followed advanced progression of MG symptoms
and a case of severe respiratory failure was reported at 6 months
after IFN discontinuation.11 The clinical courses of MG cases
by IFN for CHC were either mild or severe enough to suffer
myasthenia crisis, but most of the patients were recovered
eventually with medical care after discontinuing IFN treatment.
To our knowledge, this is the second case of thymoma-
associated MG during IFN treatment for CHC. A case of MG
that progressed to myasthenic crisis was reported at 1996 in
Japanese patient who had thymomectomy for known thymoma-
associated MG, 19 years before starting antiviral treatment.9
Thymomas are responsible for 21% of MG cases and 30% of
patients with thymoma have symptoms of MG.23,24 Myasthenic
crisis is the most serious complication of MG and thymoma is
one of the risk factors attributed to it.24
The mechanism of MG development by IFN therapy
is not completely understood, but some of the complex
FIGURE 2. Chest CT findings. There was 7-cm sized lobulated s
mediastinum. CT ¼ computed tomography.immunological actions of IFN such as enhanced lymphocyte
cytotoxicity, production of pro-inflammatory cytokines, inhi-
bition of T suppressor cell function, activation of T helper
FIGURE 3. Pathologic findings. (A) H&E stain (40) shows a multilobu
stain (100) shows thymoma B3 findings: sheet-like growth of medium
pattern); epithelial cells are mixed with a minor component of intrae
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.lymphocytes by autoantigens, and differentiation of antigen-
presenting cell might contribute to the development of IFN-
induced autoimmune diseases.25 The thymus plays a primary
role in early-onset MG mediated by anti-AChR antibodies.26
IFN-beta could play a central role in thymic events leading to
MG by triggering the overexpression of a-AChR probably
leading to thymic dendritic cells autosensitization, the abnormal
recruitment of peripheral cells, and germinal center for-
mation.26 The epithelial neoplastic cells of thymoma are
capable of presenting epitopes, which cross-reacts with differ-
ent neuromuscular antigens. In addition to AChR antibodies,
antibodies against striated muscle titin and RyR antigens are
found in most of MG thymoma patients.27
On the other, it has also been suggested that some infec-
tious viruses and HCV itself may lead to MG via mechanism of
cross-reactivity between viral epitopes and the acetylcholine
receptor.28
It is not known whether the patients who experienced MG
during IFN treatment for CHC had subclinical MG before
initiating treatment because pretreatment screening for MG is
not routinely recommended. In some patients, pre-existing
subclinical MG that might be associated with HCV infection
itself, progress to overt MG during IFN treatment, whereas, in
others, de novo MG might be induced by IFN adminis-
tration.29 In our patient, relatively large thymoma was diag-
nosed in the advanced stage after a short period of IFN
mass with internal low density and calcified portion at anterioradministration. So it seems that thymoma-associated subcli-
nical MG were unrecognized before treatment, which was
provoked by IFN administration to progress to life-threatening
lar growth pattern and infiltration into lung parenchyma. (B) H&E
-size round or polygonal cells with slight atypia (sheet-like growth
pithelial lymphocytes. H&E stain ¼ hematoxylin and eosin stain.
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myasthenic crisis. For the better understanding of clinical
implication of IFN-induced MG in CHC treatment, screening
for MG in CHC patient might be considered before starting
treatment or at least, during treatment when the patient
complained of fatigue, muscle weakness.
Screening for MG with serum anti-AChR antibody test is
simple and helpful in many patients, but it needs further
investigation in this clinical condition because some of MG
patients have serum anti-AChR antibody levels within normal
range.
CONCLUSION
In patients with CHC who is going to receive IFN-based
antiviral treatment, whether screening for thymoma or subcli-
nical MG should be included in basal evaluation is not clear but
physicians need to keep in mind the potential life-threatening
manifestations of MG before and during antiviral treatment
especially when patients complain of muscular weakness and
easy fatigability.
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